Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GenturaDx

Division of Luminex Corp.
www.genturadx.com

Latest From GenturaDx

Medical Device Deals Update, September 2012

A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.

Medical Device

Deals Shaping The Medical Industry, September 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Luminex Gains Integrated Assay System With $50 Mil. GenturaDx Purchase

Deal will enable integration of Luminex’s MultiCode-RTx technology and assays with GenturaDx’s IDbox fully automated, real-time PCR system.

Medical Device Deals

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2008

Highlights from the Q2 2008 review of device and diagnostics dealmaking: financing for medical device firms was down 9% from the first quarter to $838mm, which consisted mainly of late-stage venture rounds at 43% of the total. Big Pharma was surprisingly active in device acquisitions, with Novartis buying 25% of surgical instruments maker Alcon, and BMS selling off ConvaTec to private equity as part of its "string of pearls" strategy to focus on biotech. Two FOPOs dominated the $300mm financing the IVD/Research industry, while Invitrogen's $6.4bn stock swap for Applera's Applied Biosystems represented 90% of the M&A dollar volume.
Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Medical Devices
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Luminex Corp.
  • Senior Management
  • Mark N Bagnall, Pres. & CEO
    Dylan Bird, VP, Bus. Dev.
    Jesus Ching, PhD, CSO
  • Contact Info
  • GenturaDx
    Phone: (510) 725-4767
    24590 Clawiter Rd.
    Hayward, CA 94545
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register